Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients

被引:11
作者
Hu Yang [1 ]
Wang Mangju [1 ]
Chen Yan [2 ]
Chen Xue [1 ]
Fang Fang [1 ]
Liu Shiqin [1 ]
Zhang Ying [1 ]
Wu Xueqiang [2 ]
Zhu Ping [1 ]
机构
[1] Peking Univ, Hosp 1, Dept Hematol, Beijing 100034, Peoples R China
[2] Beijing Aerosp Gen Hosp, Inst Hematol & Oncol, Beijing 100076, Peoples R China
基金
中国国家自然科学基金;
关键词
primary systemic light chain amyloidosis; plasma cell clone; light chain restriction; immunophenotype; flow cytometry; FLOW-CYTOMETRY; MULTIPLE-MYELOMA; MONOCLONAL GAMMOPATHY; DIAGNOSIS; IMMUNOGLOBULIN; EXPRESSION; PROGNOSIS; UPDATE;
D O I
10.3760/cma.j.issn.0366-6999.20141053
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Primary systemic light chain amyloidosis (AL) is a rare plasma cell disease, our purpose was to analyze the immunophenotypic characteristics of the plasma cells in bone marrow in AL patients, and explore whether the detection of abnormal plasma cell clones in bone marrow by flow cytometry (FCM) could be used as an important indicator of AL diagnosis. Methods Fresh bone marrow samples were collected from 51 AL, 21 multiple myeloma (MM), and 5 Waldenstrom's macroglobulinemia (WM) patients. The immunophenotype of bone marrow cells were analyzed and compared by FCM using a panel of antibodies including CD45, CD38, CD138, CD117, CD56, and CD19. Results In AL, light chain restriction could be identified in 31 cases (60.9%), in which the A light chain restriction was found in 24 cases (77.4%). In MM, K light chain restriction was found in 13 cases (61.9%), and A light chain restriction in eight cases. CD45 on abnormal plasma cells was negative to weakly positive in both AL and MM, but was positive to strongly positive in WM. In the bone marrow plasma cells of the 51 AL, 78.4% were CD56+, 68.6% were CD117+, and 88.2% were CD19- While in the 21 MM cases, 66.7% were CD56+, 38.1% were CD117+, and 90.4% were CD19. The plasmacytoid lymphocytes in the five WM patients were CD19+ and CD56-, CD117-. Conclusion Detection of abnormal plasma cell clones in bone marrow by FCM is valuable for the diagnosis of AL.
引用
收藏
页码:2765 / 2770
页数:6
相关论文
共 20 条
[1]   Pitfalls in the Diagnosis of Primary Amyloidosis [J].
Chee, Cheng E. ;
Lacy, Martha Q. ;
Dogan, Ahmet ;
Zeldenrust, Steven R. ;
Gertz, Morie A. .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (03) :177-180
[2]   Systemic Light-Chain Amyloidosis: Advances in Diagnosis, Prognosis, and Therapy [J].
Cohen, Adam D. ;
Comenzo, Raymond L. .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2010, :287-294
[3]   Immunophenotype of neoplastic plasma cells in AL amyloidosis [J].
Deshmukh, M. ;
Elderfield, K. ;
Rahemtulla, A. ;
Naresh, K. N. .
JOURNAL OF CLINICAL PATHOLOGY, 2009, 62 (08) :724-730
[4]   Medical progress - The systemic amyloidoses [J].
Falk, RH ;
Comenzo, RL ;
Skinner, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (13) :898-909
[5]   Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment [J].
Gertz, Morie A. .
AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (05) :417-425
[6]   Significance of CD71 expression by flow cytometry in diagnosis of acute leukemia [J].
Liu, Qian ;
Wang, Mangju ;
Hu, Yang ;
Xing, Haizhou ;
Chen, Xue ;
Zhang, Ying ;
Zhu, Ping .
LEUKEMIA & LYMPHOMA, 2014, 55 (04) :892-898
[7]  
Manzanera Gema Mateo, 2005, V113, P5, DOI 10.1385/1-59259-916-8:5
[8]   Amyloidosis: Pathogenesis and New Therapeutic Options [J].
Merlini, Giampaolo ;
Seldin, David C. ;
Gertz, Morie A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (14) :1924-1933
[9]   An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138+ cells [J].
Nakayama, Shoko ;
Yokote, Taiji ;
Hirata, Yuji ;
Iwaki, Kazuki ;
Akioka, Toshikazu ;
Miyoshi, Takuji ;
Takayama, Ayami ;
Nishiwaki, Uta ;
Masuda, Yuki ;
Ikemoto, Toshiyuki ;
Tanaka, Hidema ;
Nishimura, Yasuichiro ;
Tsuji, Motomu ;
Hanafusa, Toshiaki .
DIAGNOSTIC PATHOLOGY, 2012, 7
[10]  
Ortolani C, 2011, FLOW CYTOMETRY OF HEMATOLOGICAL MALIGNANCIES, P1, DOI 10.1002/9781444398069